The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party
Abstract
Purpose: Early mortality in multiple myeloma (MM) is usually attributed to combined effects of active disease and comorbid factors. We have studied early deaths in a series of large multicenter trials to assess direct causes of death, their predictability, and whether current management strategies have reduced their frequency. Patients and Methods: A total of 3,107 newly diagnosed patients entered onto United Kingdom Medical Research Council MM trials from 1980 to 2002 were studied. Trial files, final clinical summaries, and postmortem reports were analyzed. Results: Death within 60 days of trial entry occurred in 299 patients (10%). Logistic regression modeling identified beta 2-microglobulin, performance status, and age as the most important predictors of early death, but only with 61% sensitivity and 73% specificity. Forty-five percent of deaths were attributable to infection, which was often associated with bone pain (particularly thoracic pain) and delay in presenting to medical care. Neutropenia was present at diagnosis in only 11 of the 135 deaths from infection. Renal failure was present in 28% of early deaths and was linked to light-chain MM, hypercalcemia, dehydration, and nonsteroidal anti-inflammatory drugs. There was no time related reduction in the percentage or nature of early deaths in 1,550 patients older than 65 years receiving similar therapy between 1982 and 2002. Conclusion: A tenth of patients die within 60 days of diagnosis of MM. Infection and renal failure are the main direct causes of early mortality, which cannot be accurately predicted by presenting prognostic features. All patients should be considered at high risk of death during induction therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Self-citationRichardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationHillner, B. E., Smith, T. J., & Desch, C. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2327 · Cited by 638
Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A. V., Morris, C., Toor, A., Siegel, E., Fink, L., et al. (2001) · Blood · doi:10.1182/blood.v98.5.1614 · Cited by 491
Bladé, J., Fernández-Llama, P., Bosch, F., Montolíu, J., Lens, X. M., Montoto, S., Cases, A., Darnell, A., Rozman, C., & Montserrat, E. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.17.1889 · Cited by 383
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Badros, A., Barlogie, B., Siegel, E., Roberts, J., Langmaid, C., Zangari, M., Desikan, R., Shaver, M. J., Fassas, A., McConnell, S., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03033.x · Cited by 306
Non-variceal upper gastrointestinal haemorrhage: guidelines
(2002) · Gut · doi:10.1136/gut.51.suppl_4.iv1 · Cited by 261
Chapel, H. M., Lee, M., Hargreaves, R., Pamphilon, D. H., Prentice, A. G., Chapel, H. M., Hargreaves, R., Lee, M., Pamphilon, D. H., & Prentice, A. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90180-5 · Cited by 260
Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia
Fahey, J. L., Scoggins, R. B., Utz, J. P., & Szwed, C. F. (1963) · The American Journal of Medicine · doi:10.1016/0002-9343(63)90140-2 · Cited by 230
Robertson, J. D., Nagesh, K., Jowitt, S. N., Dougal, M., Anderson, H., Mutton, K., Zambon, M., & Scarffe, J. H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1088 · Cited by 199
Sirohi, B., & Powles, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15736-x · Cited by 181
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis
MacLennan, I. C. M., Chapman, C. E., Dunn, J., & Kelly, K. A. (1992) · The Lancet · doi:10.1016/0140-6736(92)90004-m · Cited by 145
Self-citationZumberg, M. S., Rosario, M., Nejame, C. F., Pollock, B. H., Garzarella, L., Kao, K.-J., Lottenberg, R., & Wingard, J. R. (2002) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.2002.v8.pm12434952 · Cited by 144
Prophylactic antibiotics for the prevention of early infection in multiple myeloma
Oken, M. M., Pomeroy, C., Weisdorf, D. J., & Bennett, J. M. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00043-7 · Cited by 128
Jacobson, J. L., Hussein, M. A., Barlogie, B., Durie, B. G. M., & Crowley, J. J. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04456.x · Cited by 119
Influence of treatment and response status on infection risk in multiple myeloma
Perri, R. T., Hebbel, R. P., & Oken, M. M. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90303-x · Cited by 117
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
Rajkumar, S. V., & Greipp, P. R. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70128-3 · Cited by 116
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
Miguel, J. F. S., Lahuerta, J. J., García‐Sánz, R., Alegre, A. M., Bladé, J., Martínez, R. M. C., García‐Laraña, J., de la Rubia, J., Sureda, A. M., Vidal, M. J., et al. (2000) · The Hematology Journal · doi:10.1038/sj.thj.6200003 · Cited by 116
Grilli, R. G., Minozzi, S., Tinazzi, A., Labianca, R., Sheldon, T., & Liberati, A. (1998) · Annals of Oncology · doi:10.1023/a:1008201331167 · Cited by 100
RAYNER, H., Haynes, A. P., Thompson, J., Russell, N. H., & FLETCHER, J. (1991) · QJM · doi:10.1093/oxfordjournals.qjmed.a068572 · Cited by 85
Role of Gamma Globulin for Immunoprophylaxis in Multiple Myeloma
Salmon, S. E., Samal, B. A., Hayes, D. M., Hosley, H. F., Miller, S. P., & Schilling, A. (1967) · New England Journal of Medicine · doi:10.1056/nejm196712212772503 · Cited by 68
Bladé, J., Miguel, J. F. S., Fontanillas, M., Esteve, J., Maldonado, J., Alcalá, A., Brunet, S., García-Conde, J., Besalduch, J., Moro, M. J., et al. (2001) · The Hematology Journal · doi:10.1038/sj.thj.6200115 · Cited by 57
Ten-Year Survival in Multiple Myeloma
Alexanian, R. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360110149029 · Cited by 49
Flemming, K. D., & Brown, R. D. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.10.1330 · Cited by 47
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420522 · Cited by 34
Yussim, E., Schwartz, E., Sidi, Y., & Ehrenfeld, M. (1998) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199806)58:2<142::aid-ajh10>3.0.co;2-d · Cited by 17
Cited by
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Girmenia, C., Cavo, M., Offidani, M., Scaglione, F., Corso, A., Di Raimondo, F., Musto, P., Petrucci, M. T., & Barosi, G. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.01.001 · Cited by 662
Chen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Metadata
- Authors
- Augustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., & Drayson, M. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-20
- Volume
- 23
- Issue
- 36
- Pages
- 9219-9226
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2129126701
- Cited by
- 488
- References
- 35
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.